Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleClinical Investigation

Prediction of Hematologic Toxicity After Radioimmunotherapy with 131I-Labeled Anticarcinoembryonic Antigen Monoclonal Antibodies

Malik E. Juweid, Cun-Hui Zhang, Rosalyn D. Blumenthal, George Hajjar, Robert M. Sharkey and David M. Goldenberg
Journal of Nuclear Medicine October 1999, 40 (10) 1609-1616;
Malik E. Juweid
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cun-Hui Zhang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rosalyn D. Blumenthal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George Hajjar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert M. Sharkey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David M. Goldenberg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 40 no. 10 1609-1616
PubMed 
10520699

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X

Copyright & Usage 
COPYRIGHT© 1999 by the Society of Nuclear Medicine, Inc.

Author Information

Statistics from Altmetric.com

Cited By...

  • 35 Citations
  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

Article usage

Article usage: March 2001 to April 2025

AbstractFullPdf
Mar 2001300
Apr 2001200
Jul 2001100
Aug 2001100
Jan 2002201
Feb 2002301
Mar 2002200
Apr 2002200
May 2002200
Jul 2002102
Aug 2002100
Oct 2002201
Nov 2002101
Dec 2002401
Apr 2003101
May 2003100
Jun 2003100
Jul 2003801
Aug 20031001
Sep 2003603
Oct 2003904
Nov 20031201
Dec 2003702
Jan 2004801
Feb 2004502
Mar 2004602
Apr 2004501
May 2004601
Jun 20041400
Jul 20042600
Aug 2004401
Sep 2004201
Oct 2004701
Nov 20041105
Dec 20041101
Jan 20051000
Feb 2005600
Mar 20052904
Apr 2005300
May 2005300
Jul 2005100
Aug 2005100
Sep 2005100
Oct 2005200
Dec 2005300
Jan 2006301
Feb 2006200
Mar 2006300
Apr 2006100
May 2006301
Jun 2006100
Jul 2006301
Aug 2006001
Sep 2006703
Oct 2006303
Jan 2007409
Feb 2007504
Mar 2007403
Apr 20071004
May 2007502
Jun 2007404
Jul 2007505
Aug 2007700
Sep 2007901
Oct 20071408
Nov 2007805
Dec 2007705
Jan 2008603
Feb 2008509
Mar 200816023
Apr 20081007
May 200812017
Jun 200813011
Jul 200816012
Aug 2008604
Sep 20081106
Oct 20081603
Nov 20081108
Dec 200811010
Jan 2009504
Feb 2009306
Mar 2009707
Apr 2009606
May 2009806
Jun 2009509
Jul 200911010
Aug 20097010
Sep 2009803
Oct 20091109
Nov 20091709
Dec 200912012
Jan 20101306
Feb 20101306
Mar 20106014
Apr 2010806
May 20108011
Jun 2010409
Jul 201011013
Aug 20106011
Sep 201011012
Oct 20101207
Nov 201011012
Dec 20101208
Jan 20111306
Feb 20111205
Mar 201111014
Apr 20111509
May 20115012
Jun 20110023
Jul 20110018
Aug 20110018
Sep 20110013
Oct 20110047
Nov 20110049
Dec 20110028
Jan 20120018
Feb 20120014
Mar 20120017
Apr 20120069
May 20120022
Jun 20120015
Jul 20120022
Aug 20120021
Sep 20120020
Oct 20120019
Nov 20120014
Dec 2012007
Jan 20130016
Feb 20130010
Mar 2013008
Apr 20130012
May 20130012
Jun 2013002
Jul 2013002
Aug 2013001
Sep 2013001
Oct 2013006
Nov 2013003
Dec 2013003
Jan 2014005
Feb 2014009
Mar 2014004
Apr 2014004
May 20140010
Jun 2014005
Jul 2014004
Aug 2014011
Sep 2014003
Oct 2014013
Nov 2014004
Dec 2014005
Feb 2015005
Mar 2015006
Apr 2015006
May 2015006
Jun 2015009
Jul 20150016
Aug 2015005
Sep 2015007
Oct 2015003
Nov 2015005
Dec 2015004
Jan 2016009
Feb 2016007
Mar 2016005
Apr 2016001
May 20160013
Jun 2016008
Jul 2016005
Aug 2016009
Sep 2016004
Oct 20160015
Nov 2016002
Jan 2017003
Feb 2017002
Mar 2017003
Apr 2017002
May 2017013
Jun 2017001
Jul 2017010
Aug 2017002
Sep 2017004
Oct 2017011
Nov 2017011
Dec 2017010
Jan 2018014
Feb 2018010
May 2018022
Jun 2018001
Jul 2018002
Aug 2018002
Oct 2018002
Dec 2018003
Jan 2019002
Feb 2019005
Mar 2019005
Apr 2019002
May 2019001
Jun 2019001
Jul 2019003
Aug 2019001
Sep 2019001
Dec 20190013
Feb 2020001
Mar 2020002
Apr 2020004
May 2020005
Jun 2020001
Aug 2020003
Sep 2020001
Oct 2020005
Nov 2020006
Dec 2020004
Jan 2021102
Feb 2021107
Mar 2021101
Apr 2021008
May 2021001
Jun 2021106
Jul 20210013
Aug 20210010
Sep 2021003
Oct 2021004
Nov 2021003
Dec 2021005
Jan 2022008
Feb 2022009
Mar 2022004
Apr 2022004
May 2022206
Jun 2022001
Jul 2022002
Aug 2022003
Sep 2022107
Oct 2022003
Nov 2022102
Jan 2023008
Feb 2023009
Mar 20230011
Apr 20231031
May 2023004
Jul 2023008
Aug 2023009
Sep 2023006
Oct 2023002
Nov 2023003
Dec 2023001
Jan 2024104
Mar 2024100
Apr 2024003
May 2024101
Jun 2024005
Jul 2024004
Aug 2024005
Sep 20240012
Oct 2024106
Nov 2024002
Dec 2024004
Jan 2025006
Feb 2025006
Mar 20250017
Apr 20251028
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 40, Issue 10
October 1, 1999
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Advertising (PDF)
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Prediction of Hematologic Toxicity After Radioimmunotherapy with 131I-Labeled Anticarcinoembryonic Antigen Monoclonal Antibodies
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Prediction of Hematologic Toxicity After Radioimmunotherapy with 131I-Labeled Anticarcinoembryonic Antigen Monoclonal Antibodies
Malik E. Juweid, Cun-Hui Zhang, Rosalyn D. Blumenthal, George Hajjar, Robert M. Sharkey, David M. Goldenberg
Journal of Nuclear Medicine Oct 1999, 40 (10) 1609-1616;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Prediction of Hematologic Toxicity After Radioimmunotherapy with 131I-Labeled Anticarcinoembryonic Antigen Monoclonal Antibodies
Malik E. Juweid, Cun-Hui Zhang, Rosalyn D. Blumenthal, George Hajjar, Robert M. Sharkey, David M. Goldenberg
Journal of Nuclear Medicine Oct 1999, 40 (10) 1609-1616;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Dosimetric Analysis of 177Lu-cG250 Radioimmunotherapy in Renal Cell Carcinoma Patients: Correlation with Myelotoxicity and Pretherapeutic Absorbed Dose Predictions Based on 111In-cG250 Imaging
  • Predicting Hematologic Toxicity in Patients Undergoing Radioimmunotherapy with 90Y-Ibritumomab Tiuxetan or 131I-Tositumomab
  • Radioimmunotherapy with [131I]cG250 in Patients with Metastasized Renal Cell Cancer: Dosimetric Analysis and Immunologic Response
  • Lack of Efficacy of Two Consecutive Treatments of Radioimmunotherapy With 131I-cG250 in Patients With Metastasized Clear Cell Renal Cell Carcinoma
  • Blood-Based Red Marrow Dosimetry: Where's the Beef?
  • Prediction of Myelotoxicity Based on Bone Marrow Radiation-Absorbed Dose: Radioimmunotherapy Studies Using 90Y- and 177Lu-Labeled J591 Antibodies Specific for Prostate-Specific Membrane Antigen
  • Bone Marrow Dosimetry Using Blood-Based Models for Radiolabeled Antibody Therapy: A Multiinstitutional Comparison
  • Red Marrow Radiation Dose Adjustment Using Plasma FLT3-L Cytokine Levels: Improved Correlations Between Hematologic Toxicity and Bone Marrow Dose for Radioimmunotherapy Patients
  • Improved Prediction of Myelotoxicity Using a Patient-Specific Imaging Dose Estimate for Non-Marrow-Targeting 90Y-Antibody Therapy
  • Evaluation of Limited Blood Sampling in a Preceding 99mTc-Labeled Diagnostic Study to Predict the Pharmacokinetics and Myelotoxicity of 186Re-cMAb U36 Radioimmunotherapy
  • Genetically Engineered Tetravalent Single-Chain Fv of the Pancarcinoma Monoclonal Antibody CC49: Improved Biodistribution and Potential for Therapeutic Application
  • Google Scholar

More in this TOC Section

  • 177Lu-PSMA-617 Consolidation Therapy After Docetaxel in Patients with Synchronous High-Volume Metastatic Hormone-Sensitive Prostate Cancer: A Randomized, Phase 2 Trial
  • Transarterial Radioembolization in the TACOME Trial: Dosimetric Analysis and Clinical Features in Predicting Response and Overall Survival
  • Retreatment of Metastatic Castration-Resistant Prostate Cancer Patients with 223Ra Therapy in Daily Practice
Show more Clinical Investigation

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire